Home › Companies › NVCT

Nuvectis Pharma

NVCT Lead: Phase 1 1 Biotech Distilled article ↓

Oncology Small Molecule

Most recent annual filing: 2026-02-11

Pipeline (3 active programs)

NXP900

Small Molecule Target: SRC, YES1

Non-Small Cell Lung Cancer Phase 1 oral University of Edinburgh
Renal Cell Carcinoma Phase 1 oral University of Edinburgh
Mesothelioma Phase 1 oral University of Edinburgh

Discontinued (1)

NXP800 — Ovarian Cancer · following the completion of a Phase 1b clinical study, we decided to cease clinical development of NXP800

Biotech Distilled coverage (1)

2026-06-02 Nuvectis Pharma (NVCT) — Scientific Deep Dive for NXP900 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.